Healthcare Private Placement and M&A Transactions Review Week Ending March 16, 2025

BVI Medical: The company received $1 billion of development capital from TPG and other undisclosed investors on March 10, 2025. The company is a manufacturer of surgical devices intended for patients affected by cataracts, refractive error, glaucoma, retinal disease and dry eye.

MicroTransponder: The company raised $65 million of Series F venture funding in a deal led by U.S. Venture Partners on March 12, 2025, putting the company’s pre-money valuation at $160 million. Action Potential Venture Capital, The Vertical Group, Gilde Healthcare, Longitude Capital, Green Park & Golf Ventures, Osage University Partners and Exceller Hunt Family Office also participated in the round. The company is a developer of an implantable neurostimulation device designed to aid stroke recovery, tinnitus management, and other neurological disorders.

Shoulder Innovations: The company raised $40 million of Series E venture funding in a deal led by U.S. Venture Partners on March 10, 2025, putting the company’s pre-money valuation at $151 million. Gilde Healthcare, Gilmartin Capital, Aperture Venture Partners, Arboretum Ventures, Sectoral Asset Management, and other undisclosed investors also participated in the round. The company is a developer of a shoulder replacement implant system designed to improve outcomes related to glenoid loosening.

Vivace Therapeutics: The company raised $35 million of Series D venture funding in a deal led by RA Capital Management on March 12, 2025, putting the company’s pre-money valuation at $90 million. Canaan Partners and Cenova Capital also participated in the round. The company is an operator of a small molecule drug discovery firm intended to introduce new treatments for cancer patients.

NeuroLutions: The company raised $26.5 million of venture funding from undisclosed investors on March 14, 2025. The company is a developer of non-invasive neurorehabilitation devices designed to help stroke survivors restore lost arm function.

Syndex Bio: The company raised $15.5 million of venture funding from undisclosed investors on March 14, 2025. The company is an operator of a biotechnology platform offering molecular technologies and AI for the diagnosis and treatment of disease.

Pleco Therapeutics: The company is in process of raising EUR 13 million of Series B venture funding as of March 12, 2025. The company is a developer of therapies intended to treat cancer and improve the effectiveness of existing chemotherapy.

Strolll: The company raised GBP 10.4 million of Series A venture funding in a deal led by IW Capital on March 11, 2025, putting the company’s pre-money valuation at GBP 15 million. Cleveland Clinic and Midven also participated in the round. The company is a developer of a business-to-business digital therapeutics startup intended to deploy clinically validated rehabilitation software on off-the-shelf augmented reality (AR) glasses.

Neuromod: The company raised EUR 10 million of Series B venture funding in a deal led by Fountain Healthcare Partners and Panakes Partners on March 11, 2025. The company is a developer of a medical technology designed to stimulate progress through the design, clinical validation, and commercialization of neuromodulation technologies.

Genomate Health: The company raised $10.4 million of venture funding in the form of SAFE notes from undisclosed investors on February 11, 2025. The company is a developer of AI-powered computational tools for personalized medicine.

Vail Scientific: The company raised $7 million of venture funding from undisclosed investors on March 12, 2025. The company is a developer of medical device technology products intended to provide rapid diagnosis of diverse diseases.

Elea: The company raised EUR 4 million of venture funding led by Fly Ventures and Giant Ventures with the participation from Innovationsstarter, on March 12, 2025. The company is a developer of a healthcare AI technology designed to support healthcare workflows and medical care.

Sencure: The company raised EUR 3.9 million of Series B2 venture funding from Cottonwood Technology Fund, Noordelijke Ontwikkelings Maatschappij and 819 Capital Partners on March 11, 2025. Bluegrass Ventures also participated in the round. The company is a developer of chip technology designed for wearable medical devices and health-tracking systems.

Pacific Diabetes Technologies: The company raised $3.6 million of venture funding from TMD Ventures and other undisclosed investors on March 13, 2025. The company is a developer of hollow glucose sensor devices designed for continuous glucose monitoring and insulin delivery.

Cogvis: The company raised an undisclosed amount of venture funding in a deal led by Raiffeisen Landesbank Steiermark on March 12, 2025. The company is a developer of a fully privacy-protecting patient monitoring and care assistance system designed to provide patient-centric, autonomous, and high-quality care.

Illexcor Therapeutics: The company raised an undisclosed amount of venture funding from Zynext Ventures on March 12, 2025. The company is an operator of a biopharmaceutical business intended for the discovery and development of innovative oral therapies for sickle cell disease.

2Seventy Bio / Bristol-Myers Squibb: The company reached a definitive agreement to be acquired by Bristol-Myers Squibb for $296 million on March 10, 2025. 2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer.

Clanwilliam Group / TA Associates Management: The company entered into a definitive agreement to be acquired by TA Associates Management through a $450 million LBO on March 13, 2025. The company is a developer of healthcare software intended to serve pharmacists, acute hospitals, care homes, and private clinicians of every specialty and national healthcare organization.

Amplitude Surgical / Zydus Lifesciences: The company reached a definitive agreement to be acquired by Zydus Lifesciences for EUR 256.8 million on March 11, 2025. Amplitude Surgical is engaged in developing and marketing products for orthopedic surgery.

Centogene / Charme Capital Partners: The company was acquired by Charme Capital Partners in a  EUR 8.7 million LBO on March 12, 2025 through a public-to-private transaction. Centogene NV is a leading data-driven rare disease diagnosis and treatment company.

Epimeron / Unknown Investor: The company, a subsidiary of Willow Biosciences reached a definitive agreement to be acquired by an undisclosed investor for $3.4 million on March 14, 2025. The acquired operating subsidiary in the USA includes Willow’s biotechnology business, intellectual property, and R&D team.

Agathos / EvidenceCare: The company was acquired by EvidenceCare, via its financial sponsor Whistler Capital Partners, through an LBO on March 12, for an undisclosed amount. The company is a developer of a mobile analytics platform intended to optimize clinical practice patterns and enhance healthcare value.

Covis Pharma / Azurity Pharmaceuticals: The company was acquired by Azurity Pharmaceuticals, via its financial sponsor NovaQuest Capital Management, through an LBO on March 14, 2025 for an undisclosed amount. The company is a manufacturer of specialty pharmaceuticals intended for patients with life-threatening conditions and chronic illnesses.

Oncogeni / Nations Trust Holding: The company reached a definitive agreement to be acquired by Nations Trust Holding for an undisclosed amount on March 10, 2025. The company is a developer of cancer medicines based in Stratford-Upon-Avon, England.

Pixyl / Gleamer: The company was acquired by Gleamer for an undisclosed amount on March 11, 2025. The company is a developer of a neuroimaging cloud platform designed to improve patient care for radiologists.

TargImmune Therapeutics / iOncologi: The company was acquired by iOncologi for an undisclosed amount on March 14, 2025. The company is a developer of a nucleic acid delivery platform that uses synthetic nanoparticles to deliver therapeutics for targeted cancer treatment.